Uncategorized

DJO Incorporated’s Surgical Division and Lima Corporate Sign Product Distribution and OEM Agreement Contract

SAN DIEGO–(BUSINESS WIRE)–DJO Incorporated, a global provider of products and services that promote pain management and musculoskeletal and vascular health, announced today that its surgical division, DJO Surgical, has signed an agreement with Italian based implant company, Lima Corporate. The strategic partnership will allow Lima Corporate to distribute select DJO Surgical products in several countries in Europe, while Lima Corporate will provide products for sale in the US through DJO Surgical.

As a starting point, Lima Corporate will distribute DJO Surgical’s 3DKnee™ and Foundation™ Total Knee Systems in selected European Markets. The result of more than a decade of research, the 3DKnee is the first knee implant specifically engineered to accommodate the important changes in contact, movement, and pressure that occur in the knee joint after total knee replacement. Not only is the 3DKnee designed to provide a wider range of motion and greater stability than other knee prostheses, its revolutionary design is also intended to minimize the stresses that have traditionally led to the premature deterioration of most available implants. As a result, the 3DKnee should have a longer life expectancy than other devices, making ideal for younger patients.1

Also, as part of this first phase, DJO Surgical will pursue FDA clearance to bring to the United States Lima Corporate’s Revision Hip Stem and Acetabular Cups System, including Trabecular Titanium™. Trabecular Titanium is an innovative multi-planar hexagonal cell structure imitating the cell structure of the trabecular bone. Its morphology and dimensions have been optimized to improve vascularization and therefore maximize osteointegration. The low rigidity of the Trabecular Titanium structure fosters the transmission of physiological loads from implant to bone. It is far more resistant compared to trabecular bone, therefore it can be used as the ideal filler/support structure for bone in growth. Clinical studies have demonstrated excellent osteointegration and a Bone Implant Contact BIC of 95% in 26 weeks. Trabecular Titanium can be applied in the most diverse prosthetic implants, from initial and revision Acetabular cups to cemented cup and glenoid cages.2

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button